Mednax, Inc (MD) Shares Bought by HPM Partners LLC
HPM Partners LLC increased its stake in shares of Mednax, Inc (NYSE:MD) by 0.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,734 shares of the company’s stock after purchasing an additional 19 shares during the period. HPM Partners LLC’s holdings in Mednax were worth $708,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its position in shares of Mednax by 8.1% during the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after purchasing an additional 145 shares during the last quarter. Commonwealth Bank of Australia raised its position in shares of Mednax by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after purchasing an additional 293 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Mednax by 870.9% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock worth $139,000 after purchasing an additional 1,794 shares during the last quarter. Morgan Dempsey Capital Management LLC raised its position in shares of Mednax by 3.6% during the 1st quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock worth $157,000 after purchasing an additional 78 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of Mednax by 8.7% during the 1st quarter. Daiwa Securities Group Inc. now owns 2,500 shares of the company’s stock worth $173,000 after purchasing an additional 200 shares during the last quarter.
Shares of Mednax, Inc (NYSE:MD) opened at 41.98 on Friday. The stock has a market cap of $3.87 billion, a PE ratio of 13.37 and a beta of 0.40. The company’s 50-day moving average is $45.56 and its 200 day moving average is $58.00. Mednax, Inc has a 52 week low of $41.20 and a 52 week high of $72.13.
Mednax (NYSE:MD) last announced its earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.04. The company had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.03 earnings per share. Analysts forecast that Mednax, Inc will post $3.31 earnings per share for the current fiscal year.
In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,969 shares of Mednax stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the transaction, the director now owns 18,072 shares in the company, valued at $1,040,405.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.40% of the company’s stock.
MD has been the subject of several research analyst reports. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Stephens upgraded shares of Mednax from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $55.00 to $68.00 in a research report on Thursday, June 22nd. Jefferies Group LLC restated a “hold” rating and set a $53.00 price target (up previously from $50.00) on shares of Mednax in a research report on Thursday, July 6th. TheStreet downgraded shares of Mednax from a “b-” rating to a “c+” rating in a research report on Tuesday, May 16th. Finally, ValuEngine downgraded shares of Mednax from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. Mednax currently has a consensus rating of “Hold” and a consensus price target of $59.88.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.